We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Answers Questions on NDA-BLA Transition as March 23 Approaches
FDA Answers Questions on NDA-BLA Transition as March 23 Approaches
The FDA released final guidance yesterday on the transition of insulin and other biological products from new drug applications (NDAs) to biologics license applications (BLAs) as the March 23 transition date looms.